Positive News SentimentPositive NewsNASDAQ:AYTU Aytu BioPharma (AYTU) Stock Price, News & Analysis $2.36 +0.06 (+2.61%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.01 (+0.42%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Aytu BioPharma Stock (NASDAQ:AYTU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aytu BioPharma alerts:Sign Up Key Stats Today's Range$2.29▼$2.4050-Day Range$2.15▼$2.6552-Week Range$0.95▼$2.85Volume69,980 shsAverage Volume74,117 shsMarket Capitalization$21.19 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics. Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms. The company also offers NeoProfen (ibuprofen lysine injection) for the closure of patent ductus arteriosus in premature infants and markets an FDA-authorized rapid antigen COVID-19 self-test under license. Aytu’s products are generally distributed through specialty pharmacies, hospital networks and national wholesale distributors across the United States. Under the leadership of President and Chief Executive Officer Josh Disbrow, Aytu continues to explore licensing partnerships and in-licensing opportunities to expand its pipeline. In addition to its commercial business, the company holds exclusive rights to clinical-stage candidates addressing chronic kidney disease and other orphan indications. Aytu’s management team brings experience in life sciences finance, regulatory affairs and commercial operations as it seeks to grow both its therapeutic and diagnostic offerings and extend its reach through strategic collaborations.AI Generated. May Contain Errors. Read More Aytu BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreAYTU MarketRank™: Aytu BioPharma scored higher than 79% of companies evaluated by MarketBeat, and ranked 233rd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingAytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialAytu BioPharma has a consensus price target of $10.00, representing about 323.7% upside from its current price of $2.36.Amount of Analyst CoverageAytu BioPharma has only been the subject of 2 research reports in the past 90 days.Read more about Aytu BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aytu BioPharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.60% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aytu BioPharma has recently decreased by 1.34%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.45 Percentage of Shares Shorted8.60% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aytu BioPharma has recently decreased by 1.34%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentAytu BioPharma has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aytu BioPharma this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for AYTU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of Aytu BioPharma is held by insiders.Percentage Held by InstitutionsOnly 33.49% of the stock of Aytu BioPharma is held by institutions.Read more about Aytu BioPharma's insider trading history. Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AYTU Stock News HeadlinesLake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA AcquisitionJuly 23, 2025 | msn.comAytu Boosts Liquidity with Eclipse Loan ExtensionJuly 2, 2025 | msn.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 12 at 2:00 AM | Weiss Ratings (Ad)Lake Street Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationJuly 2, 2025 | msn.comAscendiant Capital Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationJune 30, 2025 | msn.comAytu BioPharma, Inc.: Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA - FinanzNachrichten.deJune 27, 2025 | finanznachrichten.deAytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA (TM) - MorningstarJune 24, 2025 | morningstar.comMCEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More SharesJune 14, 2025 | finance.yahoo.comSee More Headlines AYTU Stock Analysis - Frequently Asked Questions How have AYTU shares performed this year? Aytu BioPharma's stock was trading at $1.70 at the start of the year. Since then, AYTU shares have increased by 38.8% and is now trading at $2.36. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma Inc. (NASDAQ:AYTU) released its quarterly earnings results on Wednesday, May, 14th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.37. The company earned $18.45 million during the quarter, compared to the consensus estimate of $13.74 million. Aytu BioPharma had a net margin of 2.37% and a trailing twelve-month return on equity of 3.51%. Read the conference call transcript. When did Aytu BioPharma's stock split? Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017.The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Aytu BioPharma's major shareholders? Top institutional shareholders of Aytu BioPharma include Stonepine Capital Management LLC (9.05%), AWM Investment Company Inc. (6.90%), Kanen Wealth Management LLC (6.38%) and FNY Investment Advisers LLC (0.40%). Insiders that own company stock include Joshua R Disbrow and Greg Pyszczymuka. View institutional ownership trends. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE). Company Calendar Last Earnings5/14/2025Today9/12/2025Next Earnings (Estimated)9/25/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AYTU CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Price Target for Aytu BioPharma$10.00 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+319.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.84 million Net Margins2.37% Pretax Margin-0.78% Return on Equity3.51% Return on Assets0.91% Debt Debt-to-Equity Ratio0.27 Current Ratio1.03 Quick Ratio0.87 Sales & Book Value Annual Sales$81 million Price / Sales0.26 Cash FlowN/A Price / Cash FlowN/A Book Value$4.64 per share Price / Book0.51Miscellaneous Outstanding Shares8,980,000Free Float8,654,000Market Cap$21.42 million OptionableNot Optionable Beta0.22 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AYTU) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.